Cross-sectional and longitudinal analysis of the relationship between aβ deposition, cortical thickness, and memory in cognitively unimpaired individuals and in alzheimer disease

JAMA Neurology

Volumn 70, Issue 7, 2013, Pages 903-911

  Doré, Vincent ^a,b   Villemagne, Victor L ^b,c   Bourgeat, Pierrick ^a   Fripp, Jurgen ^a   Acosta, Oscar ^d   Chetélat, Gael ^e   Zhou, Luping ^a   Martins, Ralph ^f   Ellis, Kathryn A ^c,g,h   Masters, Colin L ^c   Ames, David ^g,h,i   Salvado, Oliver ^a   Rowe, Christopher C ^b  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^b AUSTIN HOSPITAL   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d UNIVERSITÉ DE RENNES 1   (France)

^e UNIVERSITÉ DE CAEN   (France)

^f EDITH COWAN UNIVERSITY   (Australia)

^g CSIRO   (Australia)

^h ST GEORGE HOSPITAL   (Australia)

ⁱ NATIONAL AGEING RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; PITTSBURGH COMPOUND B;

AGED; ALZHEIMER DISEASE; ANATOMICAL VARIATION; ARTICLE; BRAIN ATROPHY; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; CORRELATION ANALYSIS; CORTICAL THICKNESS (BRAIN); CROSS-SECTIONAL STUDY; ELECTROENCEPHALOGRAM; EPISODIC MEMORY; FEMALE; GRAY MATTER; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; LONGITUDINAL STUDY; MALE; MEMORY; MEMORY DISORDER; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRECUNEUS; PRIORITY JOURNAL; TEMPORAL LOBE;

EID: 84880272466     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2013.1062     Document Type: Article

References (47)

1. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer's disease. Alzheimers Dement. 2007;3(3):186-191.
2. Ostrowitzki S, Deptula D, Thurfjell L, et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol. 2012;69(2):198-207.
3. Price JL, Morris JC. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol. 1999;45(3):358-368.
4. Winblad B, Palmer K, Kivipelto M, et al. Mild cognitive impairment-beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med. 2004;256(3):240-246.
5. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999;56(3):303-308.
6. Chételat G, Desgranges B, De La SayetteV, Viader F, Eustache F, Baron J-C. Mapping gray matter loss with voxel-based morphometry inmild cognitive impairment. Neuroreport. 2002;13(15): 1939-1943.
7. Fan Y, Batmanghelich N, Clark CM, Davatzikos C; Alzheimer's Disease Neuroimaging Initiative. Spatial patterns of brain atrophy in MCI patients, identified via high-dimensional pattern classification, predict subsequent cognitive decline. Neuroimage. 2008;39(4):1731-1743.
8. Davatzikos C, Xu F, An Y, Fan Y, Resnick SM. Longitudinal progression of Alzheimer's-like patterns of atrophy in normal older adults: the SPARE-AD index. Brain. 2009;132(pt 8): 2026-2035.
9. Chételat G, Villemagne VL, Bourgeat P, et al; Australian Imaging Biomarkers and Lifestyle Research Group. Relationship between atrophy and beta-amyloid deposition in Alzheimer disease. Ann Neurol. 2010;67(3):317-324.
10. Bourgeat P, Chételat G, Villemagne VL, et al; AIBL Research Group. Beta-amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia. Neurology. 2010;74(2):121-127.
11. Jack CR Jr, Lowe VJ, Weigand SD, et al; Alzheimer's Disease Neuroimaging Initiative. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain. 2009;132(Pt 5):1355-1365.
12. Aizenstein HJ, Nebes RD, Saxton JA, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol. 2008;65(11):1509-1517.
13. Ingelsson M, Fukumoto H, Newell KL, et al. Early Abeta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology. 2004;62(6):925-931.
14. Engler H, Forsberg A, Almkvist O, et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain. 2006;129(pt 11):2856-2866.
15. Arnold SE, Hyman BT, Flory J, Damasio AR, Van Hoesen GW. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer's disease. Cereb Cortex. 1991;1(1):103-116.
16. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3): 306-319.
17. Pike KE, Savage G, Villemagne VL, et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain. 2007;130(pt 11): 2837-2844.
18. Rowe CC, Ellis KA, RimajovaM, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study of Aging. Neurobiol Aging. 2010;31(8):1275-1283.
19. Storandt M, Mintun MA, Head D, Morris JC. Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. Arch Neurol. 2009;66(12):1476-1481.
20. MintunMA, Larossa GN, Sheline YI, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 2006;67(3):446-452.
21. Sabuncu MR, Desikan RS, Sepulcre J, et al; Alzheimer's Disease Neuroimaging Initiative. The dynamics of cortical and hippocampal atrophy in Alzheimer disease. Arch Neurol. 2011;68(8): 1040-1048.
22. Acosta O, Bourgeat P, ZuluagaMA, Fripp J, Salvado O, Ourselin S; Alzheimer's Disease Neuroimaging Initiative. Automated voxel-based 3D cortical thickness measurement in a combined Lagrangian-Eulerian PDE approach using partial volume maps. Med Image Anal. 2009;13(5): 730-743.
23. Fischl B, Dale AM. Measuring the thickness of the human cerebral cortex frommagnetic resonance images. Proc Natl Acad Sci U S A. 2000;97(20):11050- 11055.
24. Lerch JP, Pruessner JC, Zijdenbos A, Hampel H, Teipel SJ, Evans AC. Focal decline of cortical thickness in Alzheimer's disease identified by computational neuroanatomy. Cereb Cortex. 2005;15(7):995-1001.
25. Yezzi AJ Jr, Prince JL. An Eulerian PDE approach for computing tissue thickness. IEEE Trans Med Imaging. 2003;22(10):1332-1339.
26. Morris JC, Roe CM, Grant EA, et al. Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol. 2009;66(12):1469-1475.
27. Becker JA, Hedden T, Carmasin J, et al. Amyloid-? associated cortical thinning in clinically normal elderly. Ann Neurol. 2011;69(6):1032-1042.
28. Chételat G, Villemagne VL, Villain N, et al; AIBL Research Group. Accelerated cortical atrophy in cognitively normal elderly with high ?-amyloid deposition. Neurology. 2012;78(7):477-484.
29. Dickerson BC, Bakkour A, Salat DH, et al. The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in verymild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb Cortex. 2009;19(3):497-510.
30. Rentz DM, Locascio JJ, Becker JA, et al. Cognition, reserve, and amyloid deposition in normal aging. Ann Neurol. 2010;67(3):353-364.
31. Ellis KA, Bush AI, Darby D, et al; AIBL Research Group. The Australian Imaging, Biomarkers and Lifestyle (AIBL) Study of Aging:methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. Int Psychogeriatr. 2009;21(4):672-687.
32. Rueda A, Acosta O, Couprie M, et al. Topology-corrected segmentation and local intensity estimates for improved partial volume classification of brain cortex in MRI. J Neurosci Methods. 2010;188(2):305-315.
33. Villemagne VL, Ong K, Mulligan RS, et al. Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias. J Nucl Med. 2011;52(8):1210-1217.
34. Raniga P, Bourgeat P, Fripp J, et al. Automated (11)C-PiB standardized uptake value ratio. Acad Radiol. 2008;15(11):1376-1389.
35. Acosta O, Fripp J, Doré V, et al. Cortical surface mapping using topology correction, partial flattening and 3D shape context-based non-rigid registration for use in quantifying atrophy in Alzheimer's disease. J Neurosci Methods. 2012;205(1):96-109.
36. Doré V, Fripp J, Bourgeat P, Shen K, Salvado O, Acosta O. Surface-base approach using a multi-scale EM-ICP registration for statistical population analysis. DICTA. 2011:13-18.
37. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Statist Soc B. 1995;57:289-300.
38. Mormino EC, Kluth JT, Madison CM, et al; Alzheimer's Disease Neuroimaging Initiative. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain. 2009;132(pt 5):1310-1323.
39. Buckner RL, Snyder AZ, Shannon BJ, et al. Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci. 2005;25(34):7709- 7717.
40. Buckner RL, Sepulcre J, Talukdar T, et al. Cortical hubs revealed by intrinsic functional connectivity: mapping, assessment of stability, and relation to Alzheimer's disease. J Neurosci. 2009;29(6):1860-1873.
41. Sperling RA, Laviolette PS, O'Keefe K, et al. Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron. 2009;63(2):178-188.
42. Luders E, Narr KL, Thompson PM, Rex DE, Jancke L, Toga AW. Hemispheric asymmetries in cortical thickness. Cereb Cortex. 2006;16(8): 1232-1238.
43. Scahill RI, Frost C, Jenkins R, Whitwell JL, Rossor MN, Fox NC. A longitudinal study of brain volume changes in normal aging using serial registered magnetic resonance imaging. Arch Neurol. 2003;60(7):989-994.
44. Fox NC, Warrington EK, Rossor MN. Serial magnetic resonance imaging of cerebral atrophy in preclinical Alzheimer's disease. Lancet. 1999;353(9170):2125.
45. Kaye JA, Swihart T, Howieson D, et al. Volume loss of the hippocampus and temporal lobe in healthy elderly persons destined to develop dementia. Neurology. 1997;48(5):1297-1304.
46. Chételat G, Villemagne VL, Pike KE, et al; Australian Imaging Biomarkers and Lifestyle Study of Ageing (AIBL) Research Group. Independent contribution of temporal beta-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease. Brain. 2011;134(pt 3):798-807.
47. Sperling RA, Jack CR Jr, Black SE, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research RoundtableWorkgroup. Alzheimers Dement. 2011;7(4):367-385.